文献速递外周动脉疾病

膝下腔内与外科旁路血运重建治疗GLASS II和III期慢性肢体威胁性缺血的真实世界结局

Real Life Outcomes of Infrapopliteal Endovascular and Surgical Bypass Intervention for Chronic Limb Threatening Ischaemia in GLASS Stages II and III.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2022-05-07

本观察性队列研究回顾2014年1月至2019年2月共1 427例因慢性肢体威胁性缺血(CLTI)行腹股沟下血运重建的患者病历,最终纳入326例GLASS II或III期膝下血运重建,其中腔内治疗127例、旁路移植手术199例。1年和3年无截肢生存率分别为75.2%和65.2%,总生存率分别为91.2%和83.1%。单变量分析中旁路手术后主要截肢或死亡风险高于腔内治疗(HR 1.80,95%CI 1.13-2.89;P=0.013),多变量Cox回归未发现分析变量与无截肢生存相关。

要点

  • GLASS II和III期膝下血运重建后1年无截肢生存率为75.2%、3年为65.2%。
  • 单变量分析中旁路手术较腔内治疗的主要截肢或死亡风险更高(HR 1.80)。
  • 多变量Cox回归未发现分析变量与无截肢生存相关。

核心结论

  • 经个体化团队会议决策后行膝下血运重建的GLASS II和III期CLTI患者获得了满意的无截肢生存率和总生存率。
  • 血运重建方式(腔内或开放)未影响无截肢生存结果。

研究设计与样本

  • 观察性队列研究,回顾2014年1月至2019年2月因CLTI行腹股沟下血运重建的1 427例患者病历。
  • 经详细分析后仅纳入分类为GLASS II或III期的膝下血运重建,共326例操作。
  • 127例患者接受腔内治疗,199例患者接受旁路移植手术(BGS)。
  • 主要终点为无截肢生存(AFS)和总生存(OS),次要终点为与长期AFS相关的多因素分析。

主要发现

  • 1年和3年无截肢生存率分别为75.2%和65.2%。
  • 1年和3年总生存率分别为91.2%和83.1%。
  • 单变量分析中,旁路手术后主要截肢或死亡复合终点风险高于腔内治疗后(HR 1.80,95%CI 1.13-2.89;P=0.013)。
  • 无论采用何种血运重建方式,TASC II股腘动脉D级与截肢或死亡风险升高相关(HR 1.69,95%CI 1.10-2.58;P=0.015)。
  • 多变量Cox回归分析显示所分析变量与AFS之间无关联。

关键数值与推荐

  • 无截肢生存率:1年75.2%,3年65.2%。
  • 总生存率:1年91.2%,3年83.1%。
  • 旁路手术 vs 腔内治疗的主要截肢或死亡HR 1.80(95%CI 1.13-2.89;P=0.013)。
  • TASC II股腘动脉D级与截肢或死亡的HR 1.69(95%CI 1.10-2.58;P=0.015)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Great efforts have been made to choose between bypass surgery and angioplasty as the first choice for revascularisation in chronic limb threatening ischaemia (CLTI). Endovascular therapy predominates despite limited evidence for its advantages. The purpose of this observational cohort study was to investigate outcomes after open and endovascular infrapopliteal revascularisation in extensive infrainguinal arterial disease. METHODS: The medical records of 1 427 patients who underwent infrainguinal revascularisation exclusively for CLTI in the period January 2014 to February 2019 were reviewed. After detailed analysis, only infrapopliteal revascularisations classified as GLASS stage II or III were considered, resulting in 326 procedures. In total, 127 patients underwent endovascular therapy and 199 patients underwent bypass graft surgery (BGS). The primary endpoints included amputation free survival (AFS) and overall survival (OS). Secondary endpoints included the analyses of multiple factors related to long term AFS. RESULTS: Regarding the primary endpoint, AFS was 75.2% and 65.2% at one and three years, respectively. OS at one and three years was 91.2% and 83.1%, respectively. In the univariable analysis, the hazard of the combined endpoint of major amputation or death was higher after bypass surgery than after endovascular therapy (hazard ratio [HR] 1.80, 95% confidence interval [CI] 1.13 - 2.89; p = .013). After either revascularisation method, TASC II femoropopliteal D was associated with a higher risk of amputation or death (HR 1.69, 95% CI 1.10 - 2.58; p = .015). Multivariable Cox regression analysis revealed no association between the variables analysed for AFS. CONCLUSION: Patients with CLTI submitted to infrapopliteal revascularisation and classified as GLASS II and III had satisfactory AFS and OS rates after an individualised team conference decision. Furthermore, the revascularisation modality (endovascular or open) did not influence the AFS results.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Rossi FH, Giusti JCG, Cury MVM, et al. Real Life Outcomes of Infrapopliteal Endovascular and Surgical Bypass Intervention for Chronic Limb Threatening Ischaemia in GLASS Stages II and III. Eur J Vasc Endovasc Surg. 2022. PMID: 35537642. doi:10.1016/j.ejvs.2022.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。